Fasitibant

DB15646InvestigationalSmall molecule

Fasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee).

Mechanism: Pharmacologically active on B2 bradykinin receptor
Curator reviewed
Formula / weight: C₃₆H₄₉Cl₂N₆O₆S · 764.78 g/mol (avg)

Resolves to

Compound

UNII0WL827Z7AECAS869939-83-3ChEMBLCHEMBL218427

Structure

InChIKeyFQVSDHOWSLEEKJ-LJAQVGFWSA-NSMILESCC1=NC2=C(C=CC=C2OCC2=C(Cl)C=CC(=C2Cl)S(=O)(=O)NC2(CCOCC2)C(=O)N2CCN(CC2)C(=O)[C@@H](N)CCC[N+](C)(C)C)C(C)=C1

Targets

P30411BDKRB2

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

362Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fasitibant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account